Xingqi S. Zhang

1Department Of Dermatology, No. 58, Zhongshan 2nd Road
Guangzhou, 510080, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Two Phase 3 UP-AA Randomized Clinical Trials.

Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Two Phase 3 UP-AA Randomized Clinical Trials.

Journal: JAMA dermatology

Published: August 12, 2026

Updated Integrated Safety Analysis of Ritlecitinib up to ~ 5 Years in Patients with Alopecia Areata from the ALLEGRO Clinical Trial Program.

Updated Integrated Safety Analysis of Ritlecitinib up to ~ 5 Years in Patients with Alopecia Areata from the ALLEGRO Clinical Trial Program.

Journal: American journal of clinical dermatology

Published: May 28, 2026

Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO-2b/3 and ALLEGRO-LT Clinical Studies for Alopecia Areata.

Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO-2b/3 and ALLEGRO-LT Clinical Studies for Alopecia Areata.

Journal: The Journal of dermatology

Published: September 17, 2025

Expert consensus on systemic treatment activation and grading evaluation for alopecia areata.

Expert consensus on systemic treatment activation and grading evaluation for alopecia areata.

Journal: Chinese medical journal

Published: August 16, 2025

Patient satisfaction with hair regrowth in a study of ritlecitinib: a plain language summary.

Patient satisfaction with hair regrowth in a study of ritlecitinib: a plain language summary.

Journal: Immunotherapy

Published: June 26, 2025

Polymorphism in the MLANA gene and its association with feather pigmentation in Chinese yellow quail (Coturnix japonica).

Polymorphism in the MLANA gene and its association with feather pigmentation in Chinese yellow quail (Coturnix japonica).

Journal: British poultry science

Published: February 03, 2025

Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial.

Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial.

Journal: The Journal of dermatology

Published: September 30, 2024

Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis.

Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis.

Journal: The Journal of dermatology

Published: July 11, 2024

A plain language summary on ritlecitinib treatment for adults and adolescents with alopecia areata.

A plain language summary on ritlecitinib treatment for adults and adolescents with alopecia areata.

Journal: Immunotherapy

Published: July 05, 2023

Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in Alopecia Areata: Results from ALLEGRO-2b/3.

Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in Alopecia Areata: Results from ALLEGRO-2b/3.

Journal: Dermatology (Basel, Switzerland)

Published: May 05, 2023

Hair repigmentation and regrowth in a dupilumab-treated paediatric patient with alopecia areata and atopic dermatitis: a case report.

Hair repigmentation and regrowth in a dupilumab-treated paediatric patient with alopecia areata and atopic dermatitis: a case report.

Journal: Therapeutic advances in chronic disease

Published: March 09, 2023

Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.

Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.

Journal: Lancet (London, England)

Published: October 12, 2022

Showing 1-12 of 34

Last Updated: 09/26/2026